VYNE Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
YARW$15.60+14.7%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31 | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $19,926 | $30,620 |
| Restricted cash | — | 54 |
| Investment in marketable securities (Note 6) | 41,590 | 62,633 |
| Prepaid and other current assets | 2,921 | 2,656 |
| Total Current Assets | 64,437 | 95,963 |
| Non-current Assets: | ||
| Property and equipment, net (Note 7) | 113 | — |
| Operating lease right of use assets (Note 9) | 93 | 207 |
| Non-current prepaid expenses and other assets | 2,262 | 1,515 |
| Total Non-current Assets | 2,468 | 1,722 |
| Total Assets | $66,905 | $97,685 |
| Liabilities and Shareholders’ Equity | ||
| Current Liabilities: | ||
| Trade payables | $2,707 | $1,659 |
| Accrued expenses (Note 8) | 9,272 | 4,119 |
| Employee-related obligations | 1,428 | 1,645 |
| Operating lease liabilities (Note 9) | 99 | 115 |
| Other current liabilities | 1,313 | — |
| Total Current Liabilities | 14,819 | 7,538 |
| Long-term Liabilities: | ||
| Non-current operating lease liabilities (Note 9) | — | 99 |
| Other liabilities | — | 1,313 |
| Total Long-term Liabilities | — | 1,412 |
| Total Liabilities | 14,819 | 8,950 |
| Commitments and Contingencies (Note 11) | ||
| Shareholders' Equity: | ||
| Preferred stock: $0.0001 par value; 20,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Common stock: $0.0001 par value; 150,000,000 shares authorized at December 31, 2024 and December 31, 2023; 14,830,013 and 14,098,888 shares issued and outstanding at December 31, 2024 and 2023, respectively | 1 | 1 |
| Additional paid-in capital | 783,235 | 780,044 |
| Accumulated other comprehensive income | 20 | 26 |
| Accumulated deficit | (731,170) | (691,336) |
| Total Shareholders' Equity | 52,086 | 88,735 |
| Total Liabilities and Shareholders’ Equity | $66,905 | $97,685 |
F - 2
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.